Home›Drug Pipeline› ADC resistance in bladder cancer is multifactorial, review finds, with no validated overcoming strategy
ADC resistance in bladder cancer is multifactorial, review finds, with no validated overcoming strategyNew research identifies why some bladder cancer drugs stop working
Frontiers in MedicinePublished September 13, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Recognize ADC resistance in bladder cancer as multifactorial; overcoming strategies lack trial data.
This systematic review addresses resistance to antibody-drug conjugates (ADCs) in bladder cancer, specifically locally advanced or metastatic urothelial carcinoma. Its scope covers mechanisms of resistance, strategies to overcome resistance, next-generation ADCs, combination therapies, and predictive biomarkers. Sample size, setting, comparator, and follow-up were not reported.
The central synthesized finding is that resistance to ADCs in bladder cancer is a complex process driven by multiple tumor-intrinsic and tumor-extrinsic factors. The review identifies potential strategies to overcome resistance, but it does not provide specific clinical trial data for these strategies.
Limitations were not reported, and funding or conflicts of interest were not reported. No adverse events, serious adverse events, discontinuations, or tolerability data were reported.
The authors state that understanding bladder cancer specific mechanisms of ADC resistance can help promote the development of more precise and individualized ADC-based treatment strategies. Because the review is qualitative and does not report effect sizes, confidence intervals, or trial-level outcomes, its conclusions should be interpreted as hypothesis-generating rather than practice-changing.
How this fits prior evidence
Prior coverage has addressed HER2-directed biology and therapy in bladder cancer, including an association between HER2 overexpression and higher grade, progression, and lymph node metastasis, and a case report of remission with disitamab vedotin plus tislelizumab. This review extends that context by shifting focus from target expression to the mechanisms by which bladder cancer evades ADC activity. It also complements prior coverage of splicing-derived neoantigens as immunotherapy targets, since both sources point to tumor biology, rather than a single agent, as a determinant of treatment response. No prior item reported pooled resistance mechanisms or overcoming strategies.
When a cancer treatment stops working, it can be a frustrating and difficult moment for patients and their families. For those living with bladder cancer, specifically a type called urothelial carcinoma, doctors are looking closely at a class of drugs called antibody-drug conjugates, or ADCs. These are designed to target cancer cells specifically.
This review looked into why these specific drugs sometimes fail to keep the cancer in check. The researchers found that resistance is not caused by just one thing. Instead, it is a complex process driven by many different factors inside and outside of the tumor.
Because the reasons for failure are so complex, the findings help experts understand how to create better, more individualized treatment plans. While the review identifies potential ways to overcome these hurdles, it does not provide specific clinical trial data for those new strategies yet.
What this means for you:
Resistance to bladder cancer drugs is complex, and understanding these factors helps create more precise treatments.
Common questions
Why do some bladder cancer treatments stop working?
Resistance to these drugs is a complex process. It is not caused by one single issue but is driven by multiple factors both inside and outside of the tumor. Understanding these specific mechanisms helps doctors develop more precise and individualized treatment strategies for patients with urothelial carcinoma.
What are antibody-drug conjugates?
Antibody-drug conjugates, often called ADCs, are a type of medication used to treat certain cancers, including bladder cancer. These drugs are designed to target cancer cells. This review specifically looked at how these drugs can sometimes face resistance from the tumor.
Antibody-drug conjugates (ADCs) have made important advances in the treatment of bladder cancer (BC) in recent years and have demonstrated significant clinical benefit in locally advanced or metastatic urothelial carcinoma (UC). However, the emergence of resistance remains a key factor limiting the durability of their therapeutic efficacy. Current evidence indicates that resistance to ADCs in BC is a complex process driven by multiple tumor-intrinsic and tumor-extrinsic factors. This review systematically summarizes the major mechanisms underlying ADC resistance in BC and outlines potential strategies to overcome it, including the development of next-generation ADCs, combination therapies, and predictive biomarkers. A deeper understanding of BC-specific mechanisms of ADC resistance will help promote the development of more precise and individualized ADC-based treatment strategies.
